ERBB2 and neoplasm: As novel HER2-targeting regimens enter clinical practice and more patients with ERBB2-mutated tumors are eligible for targeted therapy, the need arises to further understand the evolution of the mutational landscape in the trajectory from diagnosis to refractory disease in different tumor types [13].